MicroRNA-26b protects against MASH development in mice and can be efficiently targeted with lipid nanoparticles

Area of Science:

• Hepatology and molecular biology
• Biotechnology and drug delivery

Background:

• Metabolic dysfunction-associated steatohepatitis (MASH) prevalence is rising, necessitating research into its mechanisms.
• MicroRNA-26b (Mir26b) is implicated in pathways relevant to MASH pathogenesis.

Purpose of the Study:

• To investigate the role of Mir26b in MASH development.
• To evaluate the therapeutic potential of Mir26b mimic-loaded lipid nanoparticles (LNPs) for MASH.

Main Methods:

• Utilized Apoe-/-Mir26b-/- and Apoe-/-Lyz2creMir26bfl/fl mice fed a Western-type diet to model MASH.
• Administered Mir26b mimic-loaded LNPs to rescue MASH phenotypes.
• Validated findings in human precision-cut liver slices and employed kinase profiling.

Main Results:

• Mir26b deficiency led to increased hepatic lipids, inflammation (TNF, IL-6), macrophage infiltration, and fibrosis (Tgfb expression).
• LNP treatment reversed hepatic lipid accumulation and inflammatory signaling.
• Mir26b mimic-loaded LNPs reduced inflammation in human liver models.

Conclusions:

• Mir26b deficiency critically contributes to MASH pathogenesis.
• LNP-based delivery of Mir26b mimics offers a promising therapeutic strategy for MASH.
• This study provides novel insights into MASH mechanisms and potential LNP-based treatments.